Showing results (1-10 of 168) with videos related to
Sort By:
Pageof 17
CNS Drugs|July 13, 2015
Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's DiseaseDaphne Robakis, Stanley FahnExpert Opinion on Drug Safety|February 21, 2015
Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's diseaseMeir Kestenbaum, Stanley FahnTremor and Other Hyperkinetic Movements (New York, N.Y.)|May 27, 2017
How Much Do We Know about Adult-onset Primary Tics? Prevalence, Epidemiology, and Clinical FeaturesDaphne RobakisAnnals of the New York Academy of Sciences|July 9, 2003
Description of Parkinson's disease as a clinical syndromeStanley FahnMovement Disorders : Official Journal of the Movement Disorder Society|February 27, 2010
Parkinson's disease: 10 years of progress, 1997-2007Stanley FahnJournal of Neurology|October 14, 2005
Does levodopa slow or hasten the rate of progression of Parkinson's disease?Stanley Fahn, Movement Disorders : Official Journal of the Movement Disorder Society|December 11, 2014
The medical treatment of Parkinson disease from James Parkinson to George CotziasStanley FahnMovement Disorders : Official Journal of the Movement Disorder Society|June 1, 2011
Classification of movement disordersStanley FahnParkinsonism & Related Disorders|August 9, 2017
The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the futureStanley FahnMovement Disorders : Official Journal of the Movement Disorder Society|September 11, 2008
The history of dopamine and levodopa in the treatment of Parkinson's diseaseStanley FahnPageof 17